This work was supported by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020) and by the AgriFood XXI I&D&I project (NORTE-01-0145-FEDER-000041) cofinanced by European Regional Development Fund (ERDF) through the NORTE 2020 (Programa Operacional Regional do Norte 2014/2020). A.R.F. gratefully acknowledges the junior research position (CCECIND/02268/2017, Individual Call to Scientific Employment Stimulus 2017) granted by FCT/MCTES through national funds, and A.P.T. was supported by the Sara Borrell Research Grant (no. CD018/0123) funded by Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (A Way to Achieve Europe program).

About the Author
Dr. Freitas is a contracted investigator at the Research Unit on Applied Molecular Biosciences (UCIBIO@REQUIMTE) in the Faculty of Pharmacy of the University of Porto, Portugal. She is currently the secretary of the Food- and Water-borne Infections Study Group from the European Society of Clinical Microbiology and Infectious Diseases. Her main research interests are in the molecular epidemiology, genomics, and evolution of antimicrobial-resistant Enterococcus.

References

Highly Pathogenic Avian Influenza A(H5N8) Virus Clade 2.3.4.4b, Western Siberia, Russia, 2020

Ivan Sobolev, Kirill Sharshov, Nikita Dubovitskiy, Olga Kurskaya, Alexander Alekseev, Sergey Leonov, Yuriy Yushkov, Victor Irza, Andrey Komissarov, Artem Fadeev, Daria Danilenko, Junki Mine, Ryota Tsunekuni, Yuko Uchida, Takehiko Saito, Alexander Shestopalov

Author affiliations: Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia (I. Sobolev, K. Sharshov, N. Dubovitskiy, O. Kurskaya, A. Alekseev, A. Shestopalov); Siberian Federal Scientific Centre of Agro-BioTechnologies, Krasnoobsk, Russia (S. Leonov, Y. Yushkov); Federal Governmental State-Financed Institution Federal Centre for Animal Health, Vladimir, Russia (V. Irza); Smorodintsev Research Institute of Influenza, St. Petersburg,
Two variants of highly pathogenic avian influenza A(H5N8) virus were detected in dead poultry in Western Siberia, Russia, during August and September 2020. One variant was represented by viruses of clade 2.3.4.4b and the other by a novel reassortant between clade 2.3.4.4b and Eurasian low pathogenicity avian influenza viruses circulating in wild birds.

In 1996, the highly pathogenic avian influenza (HPAI) A(H5N1) virus subtype of the A/goose/Guangdong/1/1996 lineage was detected in domestic geese in China (1). Since 2014, H5Nx HPAI viruses belonging to clade 2.3.4.4 of A/goose/Guangdong/1/1996 lineage have spread internationally, posing a threat to the health of poultry and wild birds. Viruses of clade 2.3.4.4b have been detected in China (2013) and South Korea (2014); in 2016, reassortant strains between 2.3.4.4b and the Eurasian low pathogenicity avian influenza (LPAI) virus, for polymerase basic protein 2 (PB2), polymerase basic protein 1 (PB1), polymerase acidic gene (PA), nucleoprotein (NP), and matrix gene (M) segments, were reported in China (Qinghai Lake) and Russia (Uvs–Nuur Lake) (2). Thereafter, 2.3.4.4b viruses and their reassortant strains have spread worldwide and have been identified in poultry and wild birds in multiple countries (3).

In January and February 2020, a novel HPAI H5N8 clade 2.3.4.4b virus was detected in Germany. This virus shares 6 gene segments with the HPAI H5N8 virus in Eurasia, Asia, and Africa and 2 gene segments with LPAI virus A(H3N8), which has recently been detected in wild birds of Russia (4). HPAI virus strains closely related to isolates from Germany have also been identified in other countries of Europe, according to GISAID (https://www.gisaid.org). In October 2020, HPAI virus related to the variant from Germany has also been isolated in Japan (5) and South Korea (6).

Other variants of HPAI H5Nx virus were detected in the fall of 2020. Viruses of genetic group B of clade 2.3.4.4 and subtypes H5N8, H5N5, and H5N1 were found in Russia, Kazakhstan, and a number of countries in Europe (3,7,8). These viruses are genetically related to strains isolated in Egypt during 2017–2019 (7) and in Iraq in May 2020 (8).

The previous cases of H5 HPAI virus in Russia occurred at the end of 2018. In 2019 and the first half of 2020 H5Nx viruses had not been detected in Russia. In August and September 2020, we collected 58 samples from dead domestic birds on private rural farms in Western Siberia. We characterized 7 strains by using complete genome sequencing, phylogenetic analysis, and intravenous pathogenicity index testing. We identified all 7 strains as HPAI viruses on the basis of the amino acid sequence of the hemagglutinin (HA) proteolytic cleavage site (PLREKRRKR|G) and intravenous pathogenicity index values of 2.92–2.93 in chickens (Table).

We divided the isolated strains into 2 groups according to the sequences of the genome segments. Group 1 consists of 4 strains, whereas group 2 consists of 3 strains (Table). By using BLAST analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi), we found all 8 genome segments of group 1 and 3 genome segments (HA, M, and NS) of group 2 to be closely related (99.01%–100% nucleotide identity) to the genome segments of HPAI clade 2.3.4.4b virus strains isolated in Russia, Kazakhstan, and Europe in the summer and fall of 2020. We found the genome segments of neuraminidase, PB2, PB1, PA, and NP in group 2 to be related (98.38%–99.06% nucleotide identity) to different LPAI viruses from Eurasia.

Phylogenetic analysis showed that the whole genome of group 1 and HA, M, and nonstructural gene genome segments of group 2 clustered with HPAI H5N8 clade 2.3.4.4b virus. They were also related to H5N8 viruses from Egypt (2019) and Iraq (May 2020) but were not related to the H5N8 variants from Germany in early 2020 (Figure; Appendix 1 Figures 1–7, https://wwwnc.cdc.gov/EID/article/27/8/20-4969-App1.pdf). The neuraminidase, PB2, PB1, PA, and NP segments of group 2 viruses clustered with...
LPAI viruses identified in Eurasia. Consequently, group 2 strains are reassortant strains between Egyptian-like HPAI and LPAI viruses from Eurasia (Appendix 1 Figure 8). Of note, PB2, PA, and NP segments of group 2 isolates clustered on phylogenetic trees (nucleotide identity of 97.32%–97.45% for PB2, 98.98%–99.02% for PA, and 98.86%–99.00% for NP) with the HPAI H5N1 reassortants isolated in the fall of 2020 in the Netherlands (8, 9, 10). PB1 segments showed a lower level of identity (96.21%–96.26%). On the basis of our phylogenetic data, chronology of virus isolations, general birds' flyways, and previously described patterns of HPAI viruses spreading from Siberia during 2005–2006, 2014, and 2016–2017 (3, 9, 10), we suggest that new H5N8 viral strain from Eurasia in late 2020 possibly descended from the H5N8 virus circulating in Egypt during 2017–2019 and then disseminated through Iraq into Western Siberia and North Kazakhstan during the spring migration. Egyptian-like HPAI H5N8 virus possibly reached breeding and staging areas in Siberia in early 2020, spread in wild bird populations, and reassorted with LPAI viruses. During fall migration, standard Egyptian-like HPAI H5N8 virus and novel reassortant strains spread to the European part of Eurasia, leading to a reassortment event, which has been detected in Netherlands. However, further studies of 2020–2021 European H5Nx viruses are needed to verify this hypothesis.

Acknowledgments
We are grateful to GISAID's EpiFlu Database (http://www.gisaid.org) and to the authors who provided sequence information (Appendix 2, https://wwwnc.cdc.gov/EID/article/27/8/20-4969-App2.xlsx). Laboratory diagnostics, virologic experiments, and analysis in this study was supported by the Russian Science Foundation (project no. RSF 20-44-07001), and sample collection was supported by the Russian Foundation for Basic Research (project no. RFBR 19-54-55004). This study was also supported partly by the Ministry of Agriculture.
Forestry and Fisheries of Japan (project no. JP1008837) as part of its program for funding commissioned projects for promotion of strategic international collaborative research.

About the Author

Dr. Sobolev is a researcher at the Federal Research Center of Fundamental and Translational Medicine, Russia. His primary research interest is the molecular diagnosis and epidemiology of avian influenza viruses.

References


Address for correspondence: Ivan Sobolev, Federal Research Center of Fundamental and Translational Medicine, Timakov st. 2, Novosibirsk, 630117, Russia; email: sobolev_i@hotmail.com

Tuberculosis-Associated Hospitalizations and Deaths after COVID-19 Shelter-In-Place, San Francisco, California, USA

Janice K. Louie, Rocio Agraz-Lara, Laura Romo, Felix Crespin, Lisa Chen,1 Susannah Graves1

Author affiliations: San Francisco Department of Public Health Tuberculosis Prevention and Control Program, San Francisco, California, USA (J.K. Louie, R. Agraz-Lara, L. Romo, F. Crespin, S. Graves); University of California, San Francisco (J.K. Louie, L. Chen)

DOI: https://doi.org/10.3201/eid2708.210670

A mandated shelter-in-place and other restrictions associated with the coronavirus disease pandemic precipitated a decline in tuberculosis diagnoses in San Francisco, California, USA. Several months into the pandemic, severe illness resulting in hospitalization or death increased compared with prepandemic levels, warranting heightened vigilance for tuberculosis in at-risk populations.

Since the emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease (COVID-19), unprecedented measures have been recommended to reduce transmission. In San Francisco, California, USA, progressively restrictive health officer orders implemented since early 2020 have included travel quarantines, shelter-in-place (SIP), deferral of routine medical appointments and elective surgeries, closure of public-facing events and businesses, and isolation and quarantine when appropriate (1). Nationwide, disruptions in medical services have contributed to delaying or avoiding routine care and a decrease in non–COVID-19-related hospital admissions and emergency department visits (2). Similarly, worldwide tuberculosis (TB) case reports have declined, including in San Francisco, where a ≈60% decrease in newly diagnosed TB cases compared with prior years was observed in the first 4 months of the pandemic (3,4).

The San Francisco Department of Public Health (SFDPH) Tuberculosis Prevention and Control Program manages all cases of active TB in San Francisco residents (=881,549 population). In 2019, San Francisco had a high incidence of TB, with rates >4-fold higher (11.9 cases/100,000 persons) than the national rate. The affected population is predominantly

1These senior authors contributed equally to this article.

DOI: https://doi.org/10.3201/eid2708.210670